Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.0%Reaction day

₹1119.00

prior close

₹1048.30

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-3.6% vs market

Pharmaceuticals peers, median of 160sector-0.1%-3.9% vs sector

On the reaction day the stock moved 3.6 pts less than Nifty Smallcap 250 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.2

10m

-5.6

15m

-6.8

30m

-8.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.0-0.4-3.6-0.1-3.9

Next day

+0.8-1.9+2.7-0.9+1.7

+0.8-0.7+1.5-0.2+1.1

+2.7-0.7+3.3+0.2+2.4

+1.7+0.0+1.7+0.7+1.1

-1.2-0.1-1.1+0.2-1.4

+1.7+1.3+0.4+1.0+0.8

15d

+6.1-0.2+6.3-0.3+6.3

+7.5+3.0+4.5+1.5+6.0

+13.0+7.8+5.2+7.7+5.3

+26.9+9.1+17.8+7.6+19.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sai Life Sciences Limited reported strong full-year FY2026 results. Consolidated revenue grew 29.4% to Rs. 21,924.92 million from Rs. 16,945.70 million in FY2025. Profit after tax more than doubled to Rs. 3,489.10 million from Rs. 1,701.32 million, a 105% increase year-on-year. EBITDA margin expanded from approximately 25.6% to 30.3%. Finance costs reduced significantly from Rs. 761.64 million to Rs. 392.39 million, reflecting debt repayment from IPO proceeds. The company listed on NSE/BSE in December 2024 via an IPO raising Rs. 9,500 million in fresh capital; all IPO proceeds have been fully deployed for debt repayment and general corporate purposes. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion with no qualifications.

Likely market impact

The company delivered exceptional double-digit growth in both revenue and profitability, with margin expansion indicating improved operational efficiency. The clean audit opinion and substantial debt reduction post-IPO are positive signals for shareholders.